Investments
7Portfolio Exits
1Service Providers
3Lepu Medical Web Traffic
Lepu Medical Rank
Latest Lepu Medical News
Jul 18, 2022
(Yicai Global) July 18 -- Shanghai Kehua Bio-Engineering, Lepu Medical Technology and other Chinese Covid-19 detection kit manufacturers are forecasting an up-to-90-percent plunge in profit in the first half from the same period last year as the Chinese government calls for prices to come down more and steps up the monitoring of quality controls. Kehua Bio-Engineering’s first-half profit could crash as much as 90 percent from the year before to CNY35 million (USD5.1 million), the medical device maker said on July 14. Net profit at Lepu Medical may sink between 20 percent and 30 percent over the period to between CNY1.2 billion (USD180 million) and CNY1.3 billion, the Beijing-based company said the same day. Of this, income from its Covid-19 testing businesses could dive 80 percent. In May, the Chinese government asked testing agencies to further cut the price of nucleic acid tests to no more than CNY16 (USD2.40) each, less than half what they cost at the beginning of the year. And last month, the country’s cabinet ordered a nationwide probe into testing agencies following the frequent reporting of inaccurate test results. Some 238 labs have been told to smarten up their acts and 15 have had their licenses revoked so far. “Tighter oversight and stricter quality control requirements have pushed up the operating costs of novel coronavirus testing laboratories while revenue is shrinking,” said Lu Hongzhou, president of the Third People’s Hospital of Shenzhen. “This will cause some smaller labs to withdraw from the industry.” Even though the market share of EasyDiagnosis Biomedicine’s test kits is increasing, pricing was lower in the second quarter than in the first quarter, the Wuhan-based medical reagent maker said on July 15. To make up for the lack of manpower and testing labs, automated facilities, such as nucleic acid sampling robots, mobile testing vehicles, detection gas membranes and makeshift labs, will be on the rise. “It is urgent to improve the automation of lab testing as the higher detection efficiency and fewer man-made errors means it has a promising future," Lu said. Editor: Kim Taylor
Lepu Medical Investments
7 Investments
Lepu Medical has made 7 investments. Their latest investment was in Beijing Ruijian as part of their Series A on April 4, 2022.
Lepu Medical Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
4/7/2022 | Series A | Beijing Ruijian | Yes | 1 | ||
4/6/2022 | Series A - II | |||||
8/23/2021 | Series B | |||||
7/1/2019 | Series A | |||||
11/28/2018 | Series C |
Date | 4/7/2022 | 4/6/2022 | 8/23/2021 | 7/1/2019 | 11/28/2018 |
---|---|---|---|---|---|
Round | Series A | Series A - II | Series B | Series A | Series C |
Company | Beijing Ruijian | ||||
Amount | |||||
New? | Yes | ||||
Co-Investors | |||||
Sources | 1 |
Lepu Medical Portfolio Exits
1 Portfolio Exit
Lepu Medical has 1 portfolio exit. Their latest portfolio exit was Lepu Biotechnology on February 23, 2022.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
2/23/2022 | IPO | Public | 1 |
Date | 2/23/2022 |
---|---|
Exit | IPO |
Companies | |
Valuation | |
Acquirer | Public |
Sources | 1 |
Lepu Medical Service Providers
7 Service Providers
Lepu Medical has 7 service provider relationships
Service Provider | Associated Rounds | Provider Type | Service Type |
---|---|---|---|
IPO | Valuation Firm | Valuation | |
Service Provider | |||
---|---|---|---|
Associated Rounds | IPO | ||
Provider Type | Valuation Firm | ||
Service Type | Valuation |
Partnership data by VentureSource
You May Also Like
Quasar specializes in the manufacturing of products for the medical device market, and focuses on minimally invasive devices and disposables.
SMT develops and manufactures cardiac products in India. Its product portfolio includes coronary stents (drug-eluting and bare-metal), renal stents, angioplasty balloon catheters, and other cardiac accessories in India and abroad.

Translumina is a global Interventional cardiovascular devices company. Translumina is a fully integrated product development and manufacturing company with manufacturing facilities in Germany and India. The company commercializes products in over 50 countries globally through 2 distinct business entities, International and India.

BridgePoint Medical is focused on developing technology in the field of interventional cardiology for access to and treatment of chronic total occlusions.In September 2012, BridgePoint medical was acquired by Boston Scientific. The valuation of BridgePoint Medical was undisclosed. Other terms of the deal were not released.
Shanghai Kinetic (300326.SZ) is a medical device manufacturer for multidisciplinary specialties including Orthopedics, Cardiovascular and Sports Medicine.

Silk Road Medical develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary transcarotid therapies. By focusing on proven surgical principles and developing technology for vascular specialists, the company can improve the lives of people with carotid artery disease.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.